263 related articles for article (PubMed ID: 23308042)
1. p53-independent roles of MDM2 in NF-κB signaling: implications for cancer therapy, wound healing, and autoimmune diseases.
Thomasova D; Mulay SR; Bruns H; Anders HJ
Neoplasia; 2012 Dec; 14(12):1097-101. PubMed ID: 23308042
[TBL] [Abstract][Full Text] [Related]
2. MDM2 beyond cancer: podoptosis, development, inflammation, and tissue regeneration.
Ebrahim M; Mulay SR; Anders HJ; Thomasova D
Histol Histopathol; 2015 Nov; 30(11):1271-82. PubMed ID: 26062755
[TBL] [Abstract][Full Text] [Related]
3. MDM2 (murine double minute-2) links inflammation and tubular cell healing during acute kidney injury in mice.
Mulay SR; Thomasova D; Ryu M; Anders HJ
Kidney Int; 2012 Jun; 81(12):1199-211. PubMed ID: 22297670
[TBL] [Abstract][Full Text] [Related]
4. Double-edged swords as cancer therapeutics: novel, orally active, small molecules simultaneously inhibit p53-MDM2 interaction and the NF-κB pathway.
Zhuang C; Miao Z; Wu Y; Guo Z; Li J; Yao J; Xing C; Sheng C; Zhang W
J Med Chem; 2014 Feb; 57(3):567-77. PubMed ID: 24428757
[TBL] [Abstract][Full Text] [Related]
5. Novel derivative of benzofuran induces cell death mostly by G2/M cell cycle arrest through p53-dependent pathway but partially by inhibition of NF-kappaB.
Manna SK; Bose JS; Gangan V; Raviprakash N; Navaneetha T; Raghavendra PB; Babajan B; Kumar CS; Jain SK
J Biol Chem; 2010 Jul; 285(29):22318-27. PubMed ID: 20472557
[TBL] [Abstract][Full Text] [Related]
6. Murine Double Minute-2 Inhibition Ameliorates Established Crescentic Glomerulonephritis.
Mulay SR; Romoli S; Desai J; Honarpisheh MM; Kumar SV; Anders HJ; Thomasova D
Am J Pathol; 2016 Jun; 186(6):1442-53. PubMed ID: 27102769
[TBL] [Abstract][Full Text] [Related]
7. Targeting MDM2 for novel molecular therapy: Beyond oncology.
Wang W; Qin JJ; Rajaei M; Li X; Yu X; Hunt C; Zhang R
Med Res Rev; 2020 May; 40(3):856-880. PubMed ID: 31587329
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of MDM2 attenuates neointimal hyperplasia via suppression of vascular proliferation and inflammation.
Hashimoto T; Ichiki T; Ikeda J; Narabayashi E; Matsuura H; Miyazaki R; Inanaga K; Takeda K; Sunagawa K
Cardiovasc Res; 2011 Sep; 91(4):711-9. PubMed ID: 21498419
[TBL] [Abstract][Full Text] [Related]
9. Small molecule inhibitors of the p53-MDM2.
Hu CQ; Hu YZ
Curr Med Chem; 2008; 15(17):1720-30. PubMed ID: 18673221
[TBL] [Abstract][Full Text] [Related]
10. Podocyte loss involves MDM2-driven mitotic catastrophe.
Mulay SR; Thomasova D; Ryu M; Kulkarni OP; Migliorini A; Bruns H; Gröbmayr R; Lazzeri E; Lasagni L; Liapis H; Romagnani P; Anders HJ
J Pathol; 2013 Jul; 230(3):322-35. PubMed ID: 23749457
[TBL] [Abstract][Full Text] [Related]
11. Lipopolysaccharide downregulates the expression of p53 through activation of MDM2 and enhances activation of nuclear factor-kappa B.
Odkhuu E; Mendjargal A; Koide N; Naiki Y; Komatsu T; Yokochi T
Immunobiology; 2015 Jan; 220(1):136-41. PubMed ID: 25172547
[TBL] [Abstract][Full Text] [Related]
12. Resistance acquisition to MDM2 inhibitors.
Cinatl J; Speidel D; Hardcastle I; Michaelis M
Biochem Soc Trans; 2014 Aug; 42(4):752-7. PubMed ID: 25109953
[TBL] [Abstract][Full Text] [Related]
13. MDM2 inhibitor ameliorates cisplatin-induced nephropathy via NFκΒ signal inhibition.
Fujikura T; Yasuda H; Iwakura T; Tsuji T; Anders HJ
Pharmacol Res Perspect; 2019 Feb; 7(1):e00450. PubMed ID: 30564368
[TBL] [Abstract][Full Text] [Related]
14. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
[TBL] [Abstract][Full Text] [Related]
15. Experimental Therapy of Advanced Breast Cancer: Targeting NFAT1-MDM2-p53 Pathway.
Qin JJ; Wang W; Zhang R
Prog Mol Biol Transl Sci; 2017; 151():195-216. PubMed ID: 29096894
[TBL] [Abstract][Full Text] [Related]
16. A novel drug discovery strategy: mechanistic investigation of an enantiomeric antitumor agent targeting dual p53 and NF-κB pathways.
Zhuang C; Sheng C; Shin WS; Wu Y; Li J; Yao J; Dong G; Zhang W; Sham YY; Miao Z; Zhang W
Oncotarget; 2014 Nov; 5(21):10830-9. PubMed ID: 25350970
[TBL] [Abstract][Full Text] [Related]
17. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.
Li Q; Lozano G
Clin Cancer Res; 2013 Jan; 19(1):34-41. PubMed ID: 23262034
[TBL] [Abstract][Full Text] [Related]
18. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment.
Gupta A; Shah K; Oza MJ; Behl T
Biomed Pharmacother; 2019 Jan; 109():484-492. PubMed ID: 30551517
[TBL] [Abstract][Full Text] [Related]
19. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.
Tovar C; Rosinski J; Filipovic Z; Higgins B; Kolinsky K; Hilton H; Zhao X; Vu BT; Qing W; Packman K; Myklebost O; Heimbrook DC; Vassilev LT
Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1888-93. PubMed ID: 16443686
[TBL] [Abstract][Full Text] [Related]
20. Targeting the MDM2-p53 interaction for cancer therapy.
Shangary S; Wang S
Clin Cancer Res; 2008 Sep; 14(17):5318-24. PubMed ID: 18765522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
